Michael Egholm - 23 Feb 2026 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Reporting relationship: President & CEO, Director
Issuer ticker: LAB
Reported as of: 23 Feb 2026
Net transaction value: -$76,046
SEC form: 4
Accepted by SEC: 24 Feb 2026, 17:45:31 UTC
Prior SEC filing: 24 Nov 2025
Next SEC filing: 08 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Egholm by Tomone Tanaka, Attorney-in-Fact

Key filing fact

Michael Egholm filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 24 Feb 2026.

Key facts

This page summarizes Michael Egholm's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Feb 2026, 17:45.

Change

Previous filing in this sequence was filed on 24 Nov 2025.
Current net transaction value: -$76,046.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001559779 Primary reporting owner

Egholm Michael

Relationship: President & CEO, Director
Address: C/O STANDARD BIOTOOLS INC., 50 MILK STREET, 10TH FLOOR, BOSTON
Signature: /s/ Michael Egholm by Tomone Tanaka, Attorney-in-Fact
Signature date: 24 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LAB transaction

Common Stock

Tax liability

Transaction value: $76,046
Shares: -66,127
Change %: -1.2%
Price: $1.15
Shares after: 5,551,710
Date: 23 Feb 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024 and March 24, 2025, respectively.